Stocks to Watch: Sana Biotechnology, Richardson Electronics, Maplebear

Dow Jones

08 Jan

By Connor Hart

Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study identified no safety issues, and the hypoimmune-modified islet cells evaded immune responses. Shares surge 266%, to $6.06, in after-hours trading.

Richardson Electronics reported higher sales and a smaller loss in its fiscal second quarter. The maker of engineered solutions and green energy products said sales rose 12% to $49.5 million for the quarter ended Nov. 30. Two analysts polled by FactSet had been looking for $51.3 million. The company's loss narrowed to 5 cents a share from 13 cents a share last year, though two analysts surveyed by FactSet had expected a loss of 2 cents a share. Shares fall 6.4%, to $13.80, in postmarket trading.

Instacart parent Maplebear was selected for inclusion in the S&P MidCap 400 index. The addition will go into effect on Jan. 14, when medical-technology company Enovis will move to the S&P SmallCap 600 from the S&P MidCap 400. Enovis is replacing Arch Resources, which is being sold to CONSOL Energy. Maplebear shares rise 4.8%, to $44.99, in after-hours trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 07, 2025 18:36 ET (23:36 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2501752568"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501752568\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2501752568?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 07:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501752568","market":"hk","top_or_hot":-1,"title":"Stocks to Watch: Sana Biotechnology, Richardson Electronics, Maplebear","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study identified no safety issues, and the hypoimmune-modified islet cells evaded immune responses. Shares surge 266%, to $6.06, in after-hours trading. \n</p>\n<p>\n  Richardson Electronics reported higher sales and a smaller loss in its fiscal second quarter. The maker of engineered solutions and green energy products said sales rose 12% to $49.5 million for the quarter ended Nov. 30. Two analysts polled by FactSet had been looking for $51.3 million. The company's loss narrowed to 5 cents a share from 13 cents a share last year, though two analysts surveyed by FactSet had expected a loss of 2 cents a share. Shares fall 6.4%, to $13.80, in postmarket trading. \n</p>\n<p>\n  Instacart parent Maplebear was selected for inclusion in the S&amp;P MidCap 400 index. The addition will go into effect on Jan. 14, when medical-technology company Enovis will move to the S&amp;P SmallCap 600 from the S&amp;P MidCap 400. Enovis is replacing Arch Resources, which is being sold to CONSOL Energy. Maplebear shares rise 4.8%, to $44.99, in after-hours trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 07, 2025 18:36 ET (23:36 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Sana Biotechnology, Richardson Electronics, Maplebear</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Sana Biotechnology, Richardson Electronics, Maplebear\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-08 07:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study identified no safety issues, and the hypoimmune-modified islet cells evaded immune responses. Shares surge 266%, to $6.06, in after-hours trading. \n</p>\n<p>\n  Richardson Electronics reported higher sales and a smaller loss in its fiscal second quarter. The maker of engineered solutions and green energy products said sales rose 12% to $49.5 million for the quarter ended Nov. 30. Two analysts polled by FactSet had been looking for $51.3 million. The company's loss narrowed to 5 cents a share from 13 cents a share last year, though two analysts surveyed by FactSet had expected a loss of 2 cents a share. Shares fall 6.4%, to $13.80, in postmarket trading. \n</p>\n<p>\n  Instacart parent Maplebear was selected for inclusion in the S&amp;P MidCap 400 index. The addition will go into effect on Jan. 14, when medical-technology company Enovis will move to the S&amp;P SmallCap 600 from the S&amp;P MidCap 400. Enovis is replacing Arch Resources, which is being sold to CONSOL Energy. Maplebear shares rise 4.8%, to $44.99, in after-hours trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 07, 2025 18:36 ET (23:36 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RELL","symbol_name":"理查森电子","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2501752568","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501752568","pubTimestamp":1736292960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study identified no safety issues, and the hypoimmune-modified islet cells evaded immune responses. Shares surge 266%, to $6.06, in after-hours trading.Instacart parent Maplebear was selected for inclusion in the S&P MidCap 400 index. The addition will go into effect on Jan. 14, when medical-technology company Enovis will move to the S&P SmallCap 600 from the S&P MidCap 400. Enovis is replacing Arch Resources, which is being sold to CONSOL Energy. Maplebear shares rise 4.8%, to $44.99, in after-hours trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RELL":"理查森电子","BK4113":"食品零售","BK4585":"ETF&股票定投概念","CART":"Instacart, Inc. (Maplebear Inc.)","SANA":"Sana Biotechnology, Inc.","BK4139":"生物科技","BK4588":"碎股","BK4140":"技术产品经销商"},"translate_title":"值得关注的股票：Sana Biotechnology、Richardson Electronics、Maplebear","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CART":1,"RELL":1,"SANA":1},"content_text":"By Connor Hart \n\n\n \n\n\n  Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study identified no safety issues, and the hypoimmune-modified islet cells evaded immune responses. Shares surge 266%, to $6.06, in after-hours trading. \n\n\n  Richardson Electronics reported higher sales and a smaller loss in its fiscal second quarter. The maker of engineered solutions and green energy products said sales rose 12% to $49.5 million for the quarter ended Nov. 30. Two analysts polled by FactSet had been looking for $51.3 million. The company's loss narrowed to 5 cents a share from 13 cents a share last year, though two analysts surveyed by FactSet had expected a loss of 2 cents a share. Shares fall 6.4%, to $13.80, in postmarket trading. \n\n\n  Instacart parent Maplebear was selected for inclusion in the S&P MidCap 400 index. The addition will go into effect on Jan. 14, when medical-technology company Enovis will move to the S&P SmallCap 600 from the S&P MidCap 400. Enovis is replacing Arch Resources, which is being sold to CONSOL Energy. Maplebear shares rise 4.8%, to $44.99, in after-hours trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 07, 2025 18:36 ET (23:36 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}